Haleon plc
No enriched coverage for $HLN in the last 7 days.
No SEC Form 4 filings for $HLN in the last 30 days.
See all $HLN insider activity →Haleon said it will invest about ₹2,000 crore to build its first dedicated manufacturing plant in India, aiming to expand local production and distribution. The company reported mid-teen growth in India in the quarter ended June 2026, with Sensodyne oral health sales up over 20% in the first half. It is also pushing lower-priced packs to drive volume.
Haleon (HLN) reported first-half results in line with market expectations. The company said organic revenue grew 2.6% and adjusted operating profit rose 8.2% to £1.3bn, supported by strong operating leverage. Haleon also increased its interim dividend, but investors reacted negatively on results day.
Reuters reports Haleon shares fell after concerns about meeting sales targets. The consumer health company said first-half organic revenue grew 2.6% and adjusted operating profit rose to £1.36 billion versus £1.32 billion expected. It needs stronger second-half growth to reach a 4% to 6% medium-term target, amid weak Europe demand and a 6.5% respiratory sales decline.
Recent HLN coverage spans earnings, corporate actions and market movers.
The capex announcement is likely to be viewed as a medium-term margin and cash-flow tradeoff, with potential upside from faster local supply and demand capture.
The article frames Haleon’s results as meeting consensus but failing to impress, implying limited upside surprise and potential near-term sentiment drag.
Profit beat is being outweighed by growth-target skepticism, with regional weakness and higher freight costs pressuring the near-term outlook.
The earnings and sales beat is the primary catalyst for HLN, with the Microsoft AI partnership as a secondary strategic support.
A modest EPS miss with in-line revenue suggests limited fundamental upside from the print, but the stock’s recent strength may cushion near-term reaction.
alphai scores every news story that mentions HLN with an AI model for sentiment and relevance, and aggregates insider trades from Haleon plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Haleon said it will invest about ₹2,000 crore to build its first dedicated manufacturing plant in India, aiming to expand local production and distribution. The company reported mid-teen growth in India in the quarter ended June 2026, with Sensodyne oral health sales up over 20% in the first half. It is also pushing lower-priced packs to drive volume.
3 min readHaleon (HLN) reported first-half results in line with market expectations. The company said organic revenue grew 2.6% and adjusted operating profit rose 8.2% to £1.3bn, supported by strong operating leverage. Haleon also increased its interim dividend, but investors reacted negatively on results day.
2 min readReuters reports Haleon shares fell after concerns about meeting sales targets. The consumer health company said first-half organic revenue grew 2.6% and adjusted operating profit rose to £1.36 billion versus £1.32 billion expected. It needs stronger second-half growth to reach a 4% to 6% medium-term target, amid weak Europe demand and a 6.5% respiratory sales decline.
4 min readHaleon reported adjusted EPS of $0.14 for H1, up 16.7% from $0.12, and sales of $7.533 billion, up 6.0% year over year and far above an analyst consensus of $3.600 billion. The company also announced a new five-year collaboration with Microsoft to expand digital, data and AI capabilities using Azure and Copilot.
6 min readHaleon ADR (NYSE: HLN) reported Q2 EPS of $0.11, missing analysts’ $0.13 estimate by $0.01. Revenue was $3.65B, in line with consensus. The stock closed at $10.28, up 9.59% over 3 months and 9.01% over 12 months, according to Investing.com.
2 min readHaleon plc reported that from March 12, 2026 to June 30, 2026 it repurchased 131,447,226 shares, or 1.48%, for £457 million, completing the buyback announced March 12, 2026. The company said it operates in oral health, pain relief, digestive health, vitamins and respiratory medicines.
2 min readHaleon reported H1 2026 revenue of £5,602m, up 2.2% reported and 2.6% organically. Adjusted diluted EPS rose 12% to 10.3p, and adjusted operating profit increased to £1,364m with a 24.3% margin. Free cash flow was £769m and net debt £7.5bn. It raised the interim dividend 9% to 2.4p and kept FY 2026 guidance unchanged.
5 min readHaleon shares fell 2.2% to 371.5p after the company reported H1 2026 results. Organic revenue grew 2.6% versus a £5.62bn analyst estimate, with Q2 organic sales up 3.1% but below a 3.2% consensus. Pricing missed expectations. Haleon reaffirmed 2026 guidance and set a 2.4p interim dividend; analysts cited by Investing.com include Deutsche Bank and JPMorgan.
5 min readHaleon reported higher interim dividend and revenue growth in 1H 2026, citing Sensodyne-led momentum. Pretax profit slipped 1.8% to GBP1.06bn, while adjusted pretax profit rose 12% to GBP1.25bn, above consensus GBP1.21bn. Revenue rose 2.2% to GBP5.60bn. Interim dividend increased 9.1% to 2.4p. Outlook unchanged.
4 min readHaleon reported stronger-than-expected first-half results, with North America organic revenue growth of 3.1% in the quarter ended June 30, versus 1% in Q1 and above a 2.5% analyst expectation. Emerging markets organic growth accelerated to 6.3%. Adjusted operating profit was £1.36bn ($1.81bn), above £1.32bn consensus. Haleon kept 2026 guidance: 3% to 5% organic growth and high single-digit adjusted operating profit growth.
4 min read
